Bicycle Therapeutics plc (BCYC) Stock Score, Valuation & Financial Research
Bicycle Therapeutics plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 31/100.
Quick answer for BCYC
Bicycle Therapeutics plc currently has a Wall Street Score of 31/100. The stored market price is $3.64. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Bicycle Therapeutics plc does
Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-ta
BCYC financial snapshot
- Wall Street Score:
- 31/100
- Current price:
- $3.64
- Market capitalization:
- $252.6M
- Revenue:
- $61.2M
- Net income:
- $-190.4M
- Free cash flow:
- $-252.0M
- Cash:
- $510.1M
- Total debt:
- $13.7M
- EPS:
- -2.73
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 22/100
What stands out
- Reported year-over-year revenue growth is -0.2%.
- Free cash flow is $-252.0M, showing cash burn in the current stored period.
- The balance sheet shows $510.1M of cash versus $13.7M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BCYC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.